Li Haochuan, Yang Wanhua, Chen Peter W, Alizadeh Hassan, Niederkorn Jerry Y
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9057, USA.
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5522-8. doi: 10.1167/iovs.09-3804. Epub 2009 Jun 24.
To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and prevents liver metastases.
Human uveal melanoma cells were transfected with CXCR4 siRNA or control siRNA and tested in vitro for chemotactic and invasive behavior in response to soluble factors produced by human liver cells. The effect of CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected melanoma cells into the spleen capsules of NOD-SCID mice, and metastases were quantified by measuring the human housekeeping gene hHPRT in livers.
Blocking CXCR4 interaction with its ligand using anti-CXCL12 antibody resulted in a significant reduction in the chemotactic responses of uveal melanoma cells to soluble factors produced by human liver cells. Similarly, blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA.
CXCR4 is a key chemokine receptor that may account for the organ-specific homing of human uveal melanomas to the liver, which contains significant quantities of CXCL2, the only known ligand for CXCR4. CXCR4 is a potential therapeutic target for preventing the initial establishment of liver metastases but has limited application for use in advanced liver tumors.
确定使用小干扰RNA(siRNA)阻断趋化因子受体CXCR4的表达是否会抑制人葡萄膜黑色素瘤细胞对肝脏来源因子的趋化反应并预防肝转移。
用CXCR4 siRNA或对照siRNA转染人葡萄膜黑色素瘤细胞,并在体外测试其对人肝细胞产生的可溶性因子的趋化和侵袭行为。通过将转染的黑色素瘤细胞注射到NOD-SCID小鼠的脾包膜中来测试CXCR4 siRNA转染对肝转移形成的影响,并通过测量肝脏中的人管家基因hHPRT对转移进行定量。
使用抗CXCL12抗体阻断CXCR4与其配体的相互作用,导致葡萄膜黑色素瘤细胞对人肝细胞产生的可溶性因子的趋化反应显著降低。同样,用CXCR4 siRNA转染阻断CXCR4基因表达,可抑制暴露于人肝脏产生的因子的葡萄膜黑色素瘤细胞的趋化和侵袭特性。与未处理的葡萄膜黑色素瘤细胞或用对照siRNA转染的葡萄膜黑色素瘤细胞相比,用CXCR4 siRNA转染的葡萄膜黑色素瘤细胞产生的肝转移较少。
CXCR4是一种关键的趋化因子受体,可能是人葡萄膜黑色素瘤向肝脏器官特异性归巢的原因,肝脏中含有大量CXCL2,这是CXCR4唯一已知的配体。CXCR4是预防肝转移初始形成的潜在治疗靶点,但在晚期肝肿瘤中的应用有限。